Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Bal

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
British Journal of Haematology|January 31, 2024
Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinationsGayathri Ravi, Susan Bal, Laura Joiner, et al.
Bone Marrow Transplantation|January 9, 2021
Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantationOmer Jamy, Alice Chen, Kevin Battles, et al.
Journal of Geriatric Oncology|July 30, 2022
Disparities in clinical trial participation among older adults with multiple myeloma in the United StatesPriscila White, Abigail Cooley, Susan Bal, et al.
Blood|April 7, 2025
Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myelomaSmith Giri, Binod Dhakal, Natalie S Callander, et al.
Transplantation and Cellular Therapy|June 14, 2024
Hospital Associated Disability among Older Adults with Plasma Cell Disorders Receiving Autologous Stem Cell TransplantKyle Kidwell, Susan Bal, Kelly Godby, et al.
American Journal of Hematology|January 19, 2022
Real-world applicability of commercial chimeric antigen receptor T-cell therapy among older adults with relapsed and/or refractory multiple myelomaSmith Giri, Susan Bal, Kelly N Godby, et al.
Blood Cancer Journal|February 5, 2025
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapyLuciano J Costa, Eva Medvedova, Binod Dhakal, et al.
JAMA Oncology|September 24, 2020
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysisSmith Giri, Alyssa Grimshaw, Susan Bal, et al.
Blood Cancer Journal|April 23, 2025
Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapySusan Bal, Tylan Magnusson, Gayathri Ravi, et al.
Journal of Geriatric Oncology|May 7, 2024
Understanding health outcome preferences of older adults diagnosed with multiple myelomaSupriya Maheshwari, Miguel Arias, Clare Ubersax, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
British Journal of Haematology|January 31, 2024
Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinationsGayathri Ravi, Susan Bal, Laura Joiner, et al.
Bone Marrow Transplantation|January 9, 2021
Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantationOmer Jamy, Alice Chen, Kevin Battles, et al.
Journal of Geriatric Oncology|July 30, 2022
Disparities in clinical trial participation among older adults with multiple myeloma in the United StatesPriscila White, Abigail Cooley, Susan Bal, et al.
Blood|April 7, 2025
Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myelomaSmith Giri, Binod Dhakal, Natalie S Callander, et al.
Transplantation and Cellular Therapy|June 14, 2024
Hospital Associated Disability among Older Adults with Plasma Cell Disorders Receiving Autologous Stem Cell TransplantKyle Kidwell, Susan Bal, Kelly Godby, et al.
American Journal of Hematology|January 19, 2022
Real-world applicability of commercial chimeric antigen receptor T-cell therapy among older adults with relapsed and/or refractory multiple myelomaSmith Giri, Susan Bal, Kelly N Godby, et al.
Blood Cancer Journal|February 5, 2025
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapyLuciano J Costa, Eva Medvedova, Binod Dhakal, et al.
JAMA Oncology|September 24, 2020
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysisSmith Giri, Alyssa Grimshaw, Susan Bal, et al.
Blood Cancer Journal|April 23, 2025
Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapySusan Bal, Tylan Magnusson, Gayathri Ravi, et al.
Journal of Geriatric Oncology|May 7, 2024
Understanding health outcome preferences of older adults diagnosed with multiple myelomaSupriya Maheshwari, Miguel Arias, Clare Ubersax, et al.
Pageof 7